 FLORHAM PARK, N.J., Jan. 19, 2021 GLOBE NEWSWIRE -- Phathom Pharmaceuticals, Inc. Nasdaq: PHAT, a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has completed patient enrollment in PHALCON-HP, a pivotal Phase 3 clinical trial of vonoprazan in combination with amoxicillin vonoprazan dual therapy and vonoprazan in combination with amoxicillin and clarithromycin vonoprazan triple therapy for the eradication of H. pylori infection. Phathom continues to expect topline results from the study in the second quarter of 2021. 